Pfizer extends 10 million Yuan to earthquake victims in China

Beijing, (BUSINESS WIRE) - Today Pfizer China announced it is providing up to RMB 10 million (approximately US$1.4 million) in medicines and financial assistance to relief organizations operating in the region worst affected by the massive earthquake.

"We were devastated to hear about the rising death tolls and escalating number of injuries in Sichuan Province," said Ahmet Esen, country manager of Pfizer China. "Pfizer will work closely with the Chinese Government to provide assistance to victims of the disaster," Esen added.

Dudley Schleier, Area President for the Japan/Asia region said, "Pfizer will do its best to partner with international and local relief agencies to deliver both funds and medicines quickly and efficiently to earthquake-affected individuals."

Pfizer Inc Imraan Munshi (NY)(212) 733-6197 or Wang Zhan (Beijing) +86-10-85167741

Federal Court of Appeal in Canada upholds Lipitor Enantiomer patent

Federal Court of Appeal in Canada Upholds Lipitor Enantiomer patent, decision prevents launch of generic product by Ranbaxy until 2010

New York (BUSINESS WIRE) - Pfizer Inc said today that the Federal Court of Appeal of Canada has reversed a lower court ruling that held that Pfizer's enantiomer patent could not block generic manufacturer Ranbaxy Laboratories Limited from obtaining approval for a competitor product to Lipitor. The appellate court issued an order prohibiting regulatory approval of Ranbaxy's product in Canada until Pfizer's enantiomer (calcium salt) patent Canadian Patent No. 2,021,546?expires in July 2010.

"This decision sends a strong signal about the importance of protecting intellectual property in Canada, which provides the incentive for research-driven pharmaceutical companies to make the significant high-risk investments necessary to develop new life-saving medicines," said Pfizer Senior Vice President and Associate General Counsel Peter Richardson. "The court's ruling is not only an important one for Pfizer, but also for patients."

Ranbaxy may seek a review of the decision by the Supreme Court of Canada.

Pfizer Inc
Media Relations
Vanessa Aristide, 212-733-3784
or Investor Relations:
Suzanne Harnett, 212-733-8009